部分纯化外膜蛋白VirB9-1用于低成本抗边缘无形体纳米疫苗
边缘无形体是引起牛无形体病的蜱传病原体,目前尚无广泛接受的疫苗。本研究以部分纯化VirB9-1蛋白为抗原、中空纳米二氧化硅囊泡(SV-100)为佐剂重配纳米疫苗,简化纯化方法使抗原产量提高六倍;与纯化抗原相比,部分纯化VirB9-1配方诱导更高的抗体和细胞免疫应答。
要点
- 以部分纯化VirB9-1蛋白为抗原、SV-100纳米囊泡为佐剂重配纳米疫苗。
- 简化纯化方法获得部分纯化VirB9-1,产量提高六倍。
- 部分纯化抗原配方较纯化抗原配方诱导更高的抗体和细胞免疫应答。
核心结论
- 部分纯化VirB9-1蛋白在抗边缘无形体疫苗接种中表现优于纯化蛋白,一定水平的污染物可自佐剂并与纳米颗粒佐剂共同增强免疫原性。
- 使用部分纯化抗原联合纳米颗粒佐剂的新型纳米疫苗配方为制造更便宜的兽用疫苗提供了替代策略。
研究设计与样本
- 本研究重配纳米疫苗,以部分纯化VirB9-1蛋白为抗原、中空纳米二氧化硅囊泡(SV-100)为佐剂。
- 简化纯化方法获得部分纯化抗原VirB9-1,产量提高六倍。
主要发现
- 与纯化VirB9-1蛋白配方相比,部分纯化VirB9-1蛋白配方实现更高的抗体和细胞介导免疫应答。
临床怎么用
- 作者认为部分纯化VirB9-1蛋白在抗边缘无形体疫苗接种中表现优于纯化蛋白。
- 作者认为一定水平污染物可自佐剂并与纳米颗粒佐剂共同增强免疫原性,可能导向寻找污染物的「金发姑娘」水平。
- 作者认为使用部分纯化抗原联合纳米颗粒佐剂的新型纳米疫苗配方为制造更便宜的兽用疫苗提供了替代策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anaplasma marginale is a devastating tick-borne pathogen causing anaplasmosis in cattle and results in significant economic loss to the cattle industry worldwide. Currently, there is no widely accepted vaccine against A. marginale. New generation subunit vaccines against A. marginale, which are much safer, more efficient and cost-effective, are in great need. The A. marginale outer membrane protein VirB9-1 is a promising antigen for vaccination. We previously have shown that soluble recombinant VirB9-1 protein can be expressed and purified from Escherichia coli and induce a high level of humoral and cellular immunity in mice. In this study, we re-formulated the nanovaccines using the partially-purified VirB9-1 protein as the antigen and hollow nano-size silica vesicles (SV-100) as the adjuvant. We simplified the purification method to obtain the partially-purified antigen VirB9-1 with a six-fold higher yield. The new formulations using the partially-purified VirB9-1 protein achieved higher antibody and cell-mediated immune responses compared to the purified ones. This finding suggests that the partially-purified VirB9-1 protein performs better than the purified ones in the vaccination against A. marginale, and a certain level of contaminants in the protein antigen can be self-adjuvant and boost immunogenicity together with the nanoparticle adjuvant. This may lead to finding a "Goldilocks" level of contaminants. The new nanovaccine formulation using partially-purified antigens along with nanoparticle adjuvants offers an alternative strategy for making cheaper veterinary vaccines.
引用
- Zhao L, Cavallaro AS, Wibowo D, et al. A partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale. Vaccine. 2016. PMID: 27890399. doi:10.1016/j.vaccine.2016.11.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。